Copernicus

Copernicus Therapeutics is a private, clinical-stage biotechnology company developing non-viral genetic medicines. The company is focused on nucleic acid therapeutics enabled by STELLAR, its proprietary compacted DNA/RNA nanoparticle delivery platform designed for repeat dosing, low immunogenicity, and delivery without viral vectors. Its lead program is a mutation-agnostic cystic fibrosis gene therapy that the company describes as Phase 2b-ready based on prior Phase I/II human proof-of-concept data. Beyond cystic fibrosis, Copernicus is advancing earlier programs in rare genetic, neurologic, and ophthalmic diseases, including Stargardt's disease and opioid use disorder. The company positions its platform as suitable for delivering large genetic payloads across multiple tissues using scalable manufacturing inputs.